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ABSTRACT  
Following hindlimb ischemia (HI) increased catecholamine levels within the ischemic muscle can 
cause dysregulation of β2-adrenergic receptor (β2AR) signaling leading to reduced revascularization. 
Indeed, in vivo β2AR overexpression, via gene therapy, enhances angiogenesis in a rat model of HI. G 
protein-coupled receptor kinase 2 (GRK2) is a key regulator of βAR signaling, and βARKct, a peptide 
inhibitor of GRK2, has been shown to prevent βAR down-regulation and to protect cardiac myocytes and 
stem cells from ischemic injury, through restoration of β2AR protective signaling (i.e. Akt/eNOS). Herein, 
we tested potential therapeutic effects of adenoviral-mediated βARKct gene transfer in an experimental 
model of HI and its effects on βAR signaling and on endothelial cell (EC) function in vitro. Accordingly, 
in this study, we surgically induced HI in rats by femoral artery resection (FAR). Fifteen days of ischemia 
resulted in significant βAR down-regulation that was paralleled by an about 2-fold increase in GRK2 
levels in the ischemic muscle. Importantly, in vivo gene transfer of the βARKct in the hindlimb of rats at 
the time of FAR resulted in a marked improvement of hindlimb perfusion, with increased capillary and 
βAR density in the ischemic muscle, compared to control groups. The effect of βARKct expression was 
also assessed, in vitro in cultured ECs. Interestingly, in ECs expressing the βARKct, fenoterol, a β2AR-
agonist, induced enhanced β2AR pro-angiogenic signaling and increased EC function. In conclusion, our 
results suggest that βARKct gene-therapy and subsequent GRK2 inhibition promotes angiogenesis in a 
model of HI by preventing ischemia-induced β2AR downregulation.  
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INTRODUCTION 
Peripheral arterial occlusive disease and its most advanced form, critical limb ischemia, represent 
a major clinical problem affecting 10-15% of the aged adult population (Norgren et al., 2007). Despite 
advances in endovascular revascularization and drug therapies, its prognosis remains poor with about 
40% of patients requiring limb amputation. Therefore, new therapeutic options are urgently needed. In 
this regard, therapeutic angiogenesis has emerged as a promising investigational strategy for the treatment 
of patients with limb ischemia and gene therapy has been established as a potential method to manipulate 
levels/activity of key molecules in order to induce revascularization in patients with ischemic 
cardiovascular diseases (Rajagopalan et al., 2003; Kusumanto et al., 2006; Lederman et al., 2002; Nikol et 
al., 2008; Belch et al., 2011; Pugh and Ratcliffe, 2003). Angiogenesis is a biological process that 
generates new blood vessels from existing vasculature (Carmeliet 2005). In physiological conditions, this 
process occurs during embryonic development, pregnancy and through the ovarian cycle, but 
angiogenesis is also reactivated in a variety of pathologic conditions including ischemia, inflammation, 
wound healing, tumor growth, and diabetic retinopathy (Melillo et al., 1997; Rafii and Lyden, 2003). 
Importantly, in all these processes, angiogenesis is primarily regulated via endothelial cell (EC) 
proliferation and migration (D'Amore and Thompson, 1987). At the molecular level, it is known that the 
β2-adrenergic receptor (β2AR), the most abundant βAR isoform in ECs, is involved in the control of these 
functions (Howell et al., 1988). However, ischemia can result in increased sympathetic catecholamine 
levels that can cause β2AR signaling dysfunction in ECs, resulting in an inadequate angiogenic response 
and loss of tissue integrity and/or function (Iaccarino et al., 2005; Rengo et al., 2012). 
Mechanistically, G protein-coupled receptor kinases (GRKs) phosphorylate and desensitize 
activated βARs, thus preventing deleterious receptor overstimulation, but chronically this process 
continues through receptor internalization and degradation (Rengo et al., 2011). GRK2 is the isoform that 
appears most important for regulated βARs in muscle (Rengo et al., 2011). The βARKct, a peptide 
derived from the carboxyl terminal portion of GRK2 that blocks Gβγ recruitment of this kinase to the 
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activated membrane-embedded receptor, can inhibit βAR desensitization and improve signaling down-
regulation/desensitization (Cannavo et al., 2013a; Rengo et al., 2009b; Salazar et al., 2013). Of note, 
different reports have proposed βARKct as a new therapeutic molecule for various model of 
cardiovascular disease, mainly through the potentiation of β2AR signaling (Cannavo et al., 2013a; Khan et 
al., 2014; Salazar et al., 2013). Accordingly, since the effects of βARKct and GRK2 manipulation on EC 
function and angiogenesis is not well understood, we posited that this peptide could have the potential to 
improve post-ischemic re-vascularization through restoration of β2AR signaling/function both in vivo and 
in vitro.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JPET#228411 
 
6 
 
METHODS 
Rat hindlimb ischemia model and in vivo gene therapy. 
Hindlimb ischemia was induced in adult Sprague-Dawley male rats (300 grams) by excision of the right 
common femoral artery, as previously reported (Leosco et al. 2007). Briefly, rats were anesthetized with 
isoflurane (2%, v/v). A surgical incision was made in the skin overlying the middle portion of the right 
hind limb. After ligation of the proximal end of the femoral artery, the distal portion of the saphenous 
artery was legated, and the artery and all side branches were dissected free and excised. Then the skin was 
closed with a 2.0 silk suture. Sham-operated animals underwent the same procedure without ligation and 
excision of the right common femoral artery. In a group of rats receiving in vivo gene therapy, a silastic 
catheter was placed into the femoral artery distal to the resection, through which a solution containing 
1012 total viral particles of an adenovirus (Ad) encoding for βARKct or GFP, or vehicle (saline), was 
infused into the hindlimb and allowed to remain there for 30 minutes while the saphenous vein was 
temporarily occluded. Afterwards, the virus was removed through the catheter, the common femoral 
artery removed and the wound closed in layers. All animal care and experimental protocols were 
approved by the Ethics Committee for the Use of Animals in Research of our Institution. 
 
β-Adrenergic Receptor Radioligand Binding 
Plasma Membrane fractions from excised skeletal muscles (gastrocnemius) were prepared and used for 
βAR radioligand binding studies using the non-selective βAR antagonist ligand (125I)-Cyanopindolol (125I-
CYP), as described previously (Rengo et al. 2010). The concentration of 125I-CYP used in each series of 
reactions (assay) was 68.9 pmol/ml CYP and total activity was 5 µCi (125I-CYP specific activity: 2.2 
Ci/µmol). 
 
Cell Culture  
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Bovine aortic endothelial cells (BAECs) were purchased from Lonza and maintained in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% FBS, 200 mg/ml L-glutamine, 100 units/ml 
penicillin, and 100 μg/ml streptomycin at 37°C in 95% air and 5% CO2. For all experiments, BAECs 
were used at passage 14 or less. Primary ECs were isolated from Wild-type (WT) and global eNOS 
knockout (KO) mice. Thoracic aorta was dissected, placed rapidly in ice-cold PBS and gently flushed 
using 1-mL syringe fitted with 23-G needle to remove blood clots. After removing the fibro-adipose 
tissue and small lateral blood vessels, the aorta was cut into 1-mm rings. The aortic rings were further 
washed using sterile ice-cold PBS and then transferred in six-wells plate coated with Matrigel (Corning, 
USA). The aortic rings were then covered with few drops of matrigel and Endothelial cell growth medium 
(DMEM with 25 mM  HEPES,10% FBS, 90 μg/mL heparin sulfate, 90 μg/mL endothelial cell growth 
factor, 10,000 U/mL penicillin, 10 mg/mL streptomycin). The ECs sprouts were observed after two days. 
On the fourth-day the aortic rings were carefully removed and the ECs were allowed to proliferate in 
Matrigel until reaching confluence. To collect the ECs, matrigel were digested using dispase then cells 
were cultured to 80% confluence and then sorted for CD-31 using CD-31 Endothelial Cell Dynabeads® 
(life technology, USA) according to the manufacturer's instructions. The CD31+ cells were then plated 
and used for experimental procedures. 
BAECs and primary ECs were stimulated with fenoterol (Sigma Aldrich, USA; 1 µM) for 5, 15 
and 30 minutes and for 6 hours for immunoblot assay. While 6 and 24 hours of fenoterol stimulation were 
used to assess the EC function. Prior to fenoterol stimulation some cells was pre-treated for 30 minutes 
with the highly selective β2AR-antagonist ICI 118551 (IC50 Value: 1.2 nM (Ki); 10 µM), as previously 
reported (Cannavo et al. 2013c). 
 
Adenoviral constructs   
For in vivo and in vitro procedure we used recombinant adenoviral (Ad) vectors encoding for the bovine 
wild-type GRK2 gene (Ad-GRK2) or one encoding for the C-terminal region containing the last 194 
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amino acids of GRK2, which makes up the βARKct (Ad-βARKct). An Ad encoding for the Green 
fluorescent protein (Ad-GFP) was used as control (Lymperopoulos et al., 2008). 
 
In vitro Adenoviral infection 
Infections were accomplished on ECs at 50–60% confluence. Cells were infected with adenovirus 
expressing GRK2, βARKct or GFP as control at a MOI of 100 per cell for 24 hours at 37°C, as previously 
described (Lymperopoulos et al., 2008; Homan et al., 2014). The cells were then incubated in fresh 
medium for an additional 24 h prior to experimentation. 
 
Immunoblot 
Cells and skeletal muscle samples were lysed in a RIPA buffer with protease and phosphatase inhibitors 
cocktail (Roche, CH) as previously described (Cannavo et al., 2013b). Protein concentrations in all lysates 
were measured using a dye-binding protein assay kit (Bio-Rad, USA) and a spectrophotometer reader 
(Biorad, USA) at a wavelength of 750 nm.  Protein levels of GRK2 (Santa Cruz Biotechnology, Inc.,USA 
1:1.000), pAkt (Sigma-Aldrich, USA 1:1000), tAkt (Santa Cruz Biotechnology, Inc, USA 1:1.000), eNOS 
(Cell Signaling, 1:1000), p-eNOS (Cell Signaling, 1:1000), β2AR (Santa Cruz Biotechnology, Inc, USA 
1:1000), p-β2AR (EMD Millipore Corporation, Billerica, MA, USA 1:1000) and GAPDH (EMD 
Millipore Corporation, Billerica, MA, USA 1:1000) were assessed. Secondary antibodies were purchased 
from Amersham Life Sciences Inc. Bands were visualized by enhanced chemiluminescence (ECL; EMD 
Millipore Corporation, Billerica, MA, USA) according to the manufacturer’s instructions, and were 
quantified using densitometry (Chemidoc, Biorad, USA). Each experiment and densitometric analysis 
was separately repeated three times. 
 
Immunohistochemistry 
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Immunohistochemistry was performed as previously described (Cannavo et al. 2013b). Briefly, 
deparaffinized slides were treated with the following polyclonal antibodies: GRK2 (Santa Cruz, 1:200), 
GFP (Santa Cruz, 1:200). The visualization was performed using an ABC kit (Thermo Scientific, 
Rockford,IL, USA) and diaminobenzidine (DAB; Pierce) chromogen.  
 
Confocal microscopy 
Confocal microscopy studies were performed as previously described (Cannavo et al., 2013c). Following 
fixation with 3% paraformaldehyde, cells were incubated with an anti-β2AR antibody (1:200 anti-rabbit 
IgG, Santa Cruz) in 1% BSA.  Next, the cells were incubated with the secondary rabbit polyclonal 
antibodiy (1:200, Texas Red coniugated; Sigma). Visualization with confocal laser scanning microscopy 
was performed at 568 nm (Cy3) with a Zeiss 510 confocal laser scanning microscope. The fluorescent 
data sets were analyzed by LSM 510 software.  
 
EC function in vitro assays 
For EC proliferation and migration assays, the stimulation was performed in presence of DMEM 
supplemented with 2% FBS. Cell migration was assessed by wound-healing scratch assay performed in 
12-well tissue culture plates. Twenty-four hours after Ad infection, scratches were made using 100 µL 
pipette tips and the wells were washed twice with PBS. Following 6 hours of Fenoterol (1 µM) 
stimulation the cells were fixed in 3.7% paraformaldehyde and stained with 0.1% crystal violet staining 
solution as previously described (Liu et al. 2013). Photographs were taken on Nikon TE2000-U inverted 
microscope connected to a Nikon camera. Quantification of cell migration was done by measuring the 
distance between 10 random points within the wound edge. Gap distance of the wound was measured 
using ImageJ software, and the data were normalized to the average of the wound of control cells fixed at 
the time of scratches.  
JPET#228411 
 
10 
 
Proliferation was assessed by quantitative measurement of DNA synthesis using a 5-bromo-2'-
deoxyuridine (BrdU) ELISA kit (Roche, CH), accordingly to manufacturer instructions. Briefly, after 24 
hours from Ad infection, BrdU was added to the medium at a final concentration of 10 μM, and the cells 
were incubated for 6 or 24 hours in presence or absence of fenoterol (1 µM). BrdU incorporation was then 
assayed using a colorimetric detection system. The number of proliferating cells was represented by the 
level of BrdU incorporation, which directly correlates to the color intensity and the absorbance values.  
 
Nitric oxide (NO) measurement 
BAECs or murine aortic endothelial cells, infected with Ad-βARKct and –GFP, were stimulated or not 
with fenoterol (1 µM) for 6 hours. Following stimulation, the concentrations of nitric oxide (NO) in the 
culture medium were measured using the NO colorimetric assay kit (BioVision, Mountain View, CA) 
according to the manufacturer’s protocol. Briefly, the nitrate was converted to nitrite utilizing nitrate 
reductase, then the nitrite was converted to a deep purple azo compound using Griess reagent. The 
amount of the azochromophore was detected by the colorimetric determination at 540 nm using a 
microplate reader. 
 
Blood flow determination 
Blood flow (BF) in the posterior tibial artery of ischemic and non-ischemic hindlimb was evaluated by 
ultrasound (US) Doppler (using a Visual SONICS VeVo 770 imaging system with a 708 MHz scanhead) 
in isofluorane-anaesthetized rats (2% v/v) immediately before and at 12 hours, 3, 7, 10 and 15 days after 
surgery, as previously described (Ciccarelli et al., 2011). Data are expressed as ischemic to non-ischemic 
ratio. Fifteen days after surgery, blood flow was also measured by dyed beads assay, as previously 
described (Ciccarelli et al., 2011). 
 
Histology 
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Tibialis anterior muscle specimens were fixed in 4% paraformaldehyde and embedded in paraffin. After 
deparaffinization and rehydration, 5-μm-thick sections were prepared, mounted on glass slides. Capillary 
density was performed as previously described (Ciccarelli et al., 2011; Rengo et al., 2013).  
 
Statistical analysis 
Data are summarized as mean±SEM. Comparisons were made with the use of t-tests or ANOVA, as 
appropriate. A Bonferroni correction was applied to the probability values whenever multiple 
comparisons arose. Values of p<0.05 were considered significant.
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RESULTS 
βARKct gene-therapy improves angiogenesis and restores βAR density in the ischemic hindlimb. 
Following hindlimb ischemia (HI), increased levels of catecholamines (CAs) are responsible for 
βAR-signaling dysfunction, leading to reduced angiogenesis in the ischemic tissue (Sorriento et al., 2012; 
Iaccarino et al., 2005). Importantly, a similar mechanism has been observed also in the heart, where 
βARKct gene-therapy has been proposed as a potential strategy to prevent βAR dysregulation and to 
ameliorate cardiac response to ischemia (White et al., 2000). However, the effects of βARKct gene-
therapy in a model of HI have not been specifically investigated. Thus, we surgically induced HI in adult 
male Sprague-Dawley rats by resection of the right common femoral artery (FAR). A group of sham-
operated rats served as control. At 15 days post-surgery, blood flow was measured by a dyed beads 
perfusion assay showing a significant reduction in hindlimb perfusion in the ischemic muscle of the group 
undergoing FAR compared to sham-operated rats, as expected (Figure 1A). In line with previous reports 
(Iaccarino et al., 2005), 2 weeks after surgically induced ischemia, we observed a significant reduction in 
βAR density within the ischemic skeletal muscle compared to the skeletal muscle of sham-operated rats 
(Figure 1B). The reduction in βAR plasma membrane density was paralleled by a robust up-regulation of 
GRK2 protein levels in the ischemic skeletal muscle compared with the limbs of sham-operated rats 
(Figure 1C). Next, to test the effects of βARKct expression, a group of rats was injected into the femoral 
artery with an Adenovirus (Ad) encoding for βARKct (Ad-βARKct) or Ad-GFP, as control, at the time of 
FAR. A separate group of animals were treated with a saline injection, to provide an additional control to 
assess any potential effect of Ad infection or GFP expression (Figure 2A). At the end of the study period, 
transgene expression was successfully detected by immunohistochemistry and resulted in predominant 
perivascular localization (Figure 2B). However, consistent with previous reports (Iaccarino et al. 2005), 
transgene expression was not limited to the endothelium, but was also observed in the skeletal muscle. 
Moreover, we assessed βARKct expression in the ischemic skeletal muscle of rats at the end of the study 
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period by immunoblotting (Figure 2C). As expected, βARKct was clearly detectable in the muscle of rats 
treated with Ad-βARKct (Figure 2D). 
Next, to evaluate the effects of βARKct gene-therapy on post-ischemic angiogenesis, blood flow 
was measured in all groups by Doppler over the course of 15-day study period. As shown in figure 3A, 
immediately after FAR, blood flow was not detectable in the ischemic tibial posterior artery of all study 
groups. As expected, blood flow was partially and progressively restored in rats treated with saline or 
GFP over the 15-day study period (Figure 3A). However, βARKct gene therapy resulted in a significant 
increase in blood flow compared to control groups (Figure 3A). Data from the dyed beads perfusion 
assay confirmed these results (Figure 3B). In line with blood flow and perfusion data, histological 
analysis of the tibial anterior muscle revealed that 15 days of hindlimb ischemia induced a robust 
capillary rarefaction in saline- and Ad-GFP-treated rats (Figure 3C). Of note, we found a complete 
restoration of the capillary density in βARKct treated ratsthat was not statistically different to that 
measured in sham-operated animals (Figure 3C).  
Finally, we assessed βAR plasma membrane density in the ischemic gastrocnemius from all study 
groups (Figure 3D). In line with previous reports (Iaccarino et al., 2005), a significant down-regulation of 
total βAR density was observed in saline- and GFP-treated groups compared to sham-operated animals. 
More importantly, βARKct gene-therapy resulted in the restoration of βAR density in the ischemic 
muscles, at levels that were almost similar to sham groups. 
 
βARKct improves in vitro β2AR-signaling in Endothelial cells (ECs). 
Our in vivo data showing that βARKct-dependent re-vascularization is associated with a 
restoration of βAR density in the ischemic skeletal muscle prompted us to investigate the effects of this 
peptide on EC function. Bovine aortic ECs (BAECs) were stimulated in vitro with the selective β2AR-
agonist fenoterol (1 μM) (January et al., 1997) to test activation of Akt and endothelial NO synthase 
(eNOS), since these protein are known to be nodal regulators of EC function (Howell et al., 1988). 
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Indeed, we found that fenoterol was able to increase both Akt and eNOS activation following 15 minutes 
of stimulation (Figure 4A-B). Notably, pre-treatment of cells for 30 minutes with the selective β2AR 
antagonist ICI-118,551 (10 μM) completely prevented the ability of fenoterol to increase in Akt and 
eNOS phosphorylation (Figure 4A-B), indicating that these effects are completely dependent on β2AR 
activation. Next, ECs were infected in vitro with Ad-GRK2 or Ad-βARKct or Ad-GFP (as control) and, 
we assessed the effects of fenoterol on β2AR phosphorylation/desensitization (p-β2AR), by measuring 
phospho-threonine (pThr) 384 levels of the bovine β2AR (i.e. the homologous residue to the threonine 
targeted by GRK2 in the human β2AR, triggering rapid receptor desensitization) (Fredericks et al., 1996). 
In absence of agonist stimulation, there were no differences in terms of β2AR phosphorylation between 
GFP, GRK2 and βARKct infected cells (Figure 5A). Five minutes of fenoterol stimulation resulted in a 
significant increase in p-β2AR levels in all EC groups compared to unstimulated ECs. However, GRK2 
overexpression induced a further significant increase in p-β2AR levels compared to both GFP and 
βARKct cells, suggesting that increased GRK2 activity is responsible for augmented β2AR 
phosphorylation and consequent desensitization also in ECs (Figure 5A). Next, we tested the direct 
effects of GRK2 and βARKct on fenoterol-dependent Akt and eNOS activation (Queen et al., 2006; 
Figueroa et al., 2009).  Indeed, in GFP- and in βARKct-treated cells, 15 minutes of fenoterol 
administration induced a significant enhancement in both Akt and eNOS phosphorylation (Figure 5B-C), 
while GRK2 overexpression resulted in a blunted activation of these factors. Notably, following 15 
minutes of fenoterol stimulation no significant changes in GRK2 protein levels were observed between 
GFP- and in βARKct-infected cells (Figure 5D).  
Next, we tested the impact of longer fenoterol stimulation on β2AR signaling in ECs. 
Interestingly, following 6 hours of fenoterol administration, GRK2 expression was increased in both GFP 
and βARKct cells, at levels almost comparable, but statistically different, to those observed in Ad-GRK2 
treated cells (Figure 6A). However, a robust β2AR phosphorylation/desensitization was evident only in 
GFP and GRK2 cells. Further, p-β2AR levels were significantly reduced in presence of βARKct (Figure 
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6B). Consistent with increased β2AR desensitization, long-term fenoterol stimulation resulted in 
decreased Akt (Figure 6C) and eNOS (Figure 6D) activation in both GFP and GRK2 overexpressing 
cells. In contrast, the presence of βARKct, which prevented β2AR phosphorylation and subsequent 
desensitization (Figure 6B), resulted in an increased activation of Akt and eNOS, at levels comparable to 
basal unstimulated conditions (Figure 6C-D). These results strongly suggest a potential role of βARKct 
in preventing GRK2-dependent β2AR phosphorylation and consequent receptor down-regulation. In order 
to confirm this hypothesis, we performed plasma membrane purifications in extracts obtained from 
BAECs infected with GFP and βARKct, and either left un-stimulated or stimulated with both with 
fenoterol for 6 hours, and we found a significant reduction in β2AR plasma membranes levels in GFP 
cells (Figure 7A-B). Further, internalized β2AR levels were increased compared to unstimulated cells. In 
contrast, βARKct expression prevented the effects of fenoterol on β2AR-plasma membrane 
downregulation (Figure 7A-B). In line with these results, confocal microscopy experiments, confirmed 
that β2AR was mainly localized at cytosolic level following fenoterol stimulation in GFP ECs (Figure 
7C). In contrast, βARKct expression resulted in predominant β2AR localization at the plasma membrane 
similar to that observed in unstimulated cells (Figure 7C).  
 
βARKct enhances in vitro EC function in response to selective β2AR stimulation 
Since, our data above showed that βARKct prevented the fenoterol induced β2AR 
desensitization/downregulation and rescued associated pro-angiogenic signaling, we evaluated the effects 
of β2AR-agonism on EC function. We first assessed NO release, since it has been demonstrated to be a 
potential modulator of EC function. As showed in Figure 8A, following 6 hours of fenoterol stimulation, 
we observed a significant increase in NO release in GFP cells, compared to unstimulated ones. Of note, 
following fenoterol stimulation in the presence of βARKct, we observed a more pronounced NO release 
compared to all cell groups.  
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Next, we assessed the effects of β2AR-agonism on EC function. We evaluated EC migration 
performing a wound healing scratch assay under basal condition and after challenge with β2AR agonist. 
As shown in Figure 8B, under basal conditions, the expression of βARKct did not induce any significant 
effect on cell migration compared to GFP cells. Importantly, fenoterol stimulation resulted in a ≈2-fold 
increase in migration in GFP cells and, the presence of βARKct, induced significantly enhanced EC 
migration in response to β2AR stimulation that was almost double to that observed in control GFP cells. 
Similar results were obtained in an EC proliferation assessed by 5-bromo-2'-deoxyuridine (BrdU) 
incorporation (Figure 8C). Fenoterol induced a significant increase in EC proliferation in GFP cells 
compared to non-stimulated cells at both 6 and 24 hours, and βARKct expression induced a robust 
proliferative response to β2AR-agonism that was significantly higher than that observed in GFP treated 
cells at both time points (Figure 8C). 
Finally, in order to study the role of βARKct on β2AR-dependent eNOS activation, we isolated 
primary ECs from the aorta of wild-type (WT) and eNOS knockout (KO) mice. The ECs were then 
infected with Ad-GFP and Ad-βARKct. Importantly, the lack of eNOS almost completely prevented the 
effects of βARKct on fenoterol-dependent increase in EC migration (Figure 9A) and proliferation 
(Figure 9B) compared to WT cells. In line with these results, at molecular level, we observed that the 
lack of eNOS abolished the ability of βARKct to activate/rescue β2AR-dependent Akt activation 
(Supplemental Figure 1A-B) and to increase NO release following fenoterol stimulation (Figure 9C).  
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DISCUSSION 
There is extensive literature supporting the therapeutic value of βARKct gene therapy to 
ameliorate cardiac function and remodeling following MI (Cannavo et al. 2013a), especially for its ability 
to block GRK2-dependent β2AR dysfunctional signaling (Cannavo et al. 2013a, Khan et al., 2014; Salazar 
et al., 2013).  Herein, we report for the first time the effects of βARKct gene therapy in a rat model of 
hindlimb ischemia (HI). In particular, we show that βARKct is a new potential therapeutic tool to 
improve post-ischemic angiogenesis through preservation of β2AR signaling in the endothelium. We 
observed that ischemia induces the up-regulation of GRK2 protein levels in skeletal muscle and this event 
appears to be critical in the processes of re-vascularization of the ischemic hindlimb, since it is associated 
with βAR-desensitization/downregulation. Importantly, the present study confirms the relevant role of 
endothelial β2AR in the control of re-vascularization in vivo and EC function in vitro. In this context, 
previous studies have reported a crucial role of β2AR at promoting in vivo post-ischemic revascularization 
and, in particular, its functional relevance in the regulation of EC function in vitro has emerged as a key 
mechanism (Iaccarino et al., 2005). β2AR KO mice exhibited impaired re-vascularization following 
ischemia with a high rate of tissue necrosis and subsequent auto-amputation of ischemic limbs (Iaccarino 
et al., 2005). Moreover, in a rat model of HI, when β2AR is downregulated, gene therapy using the 
receptor resulted in improved revascularization of the ischemic limb (Iaccarino et al., 2005). 
Importantly, no mechanism has been proposed for triggering ischemic-mediated β2AR 
dysfunction. Accordingly, the ability of GRK2 to regulate βAR signaling and function in the heart has 
been well established (Cannavo et al., 2013a; Huang et al., 2011) and therapies that inhibit the activity of 
this kinase on receptor phosphorylation/downregulation at the plasma membrane have been shown to be 
strongly protective towards cardiac injury and stress in part, by restoring myocardial βAR signaling 
abnormalities (Cannavo et al., 2013a; Rengo et al., 2009a; Rengo et al., 2011). Herein, we show that the 
resection of the common femoral artery in rats, a well recognized model of peripheral artery disease 
(Leosco et al., 2007; Iaccarino et al., 2005), results in ≈2-fold increase in GRK2 levels in the ischemic 
JPET#228411 
 
18 
 
gastrocnemius compared to sham-operated rats. Moreover, we confirmed that GRK2 up-regulation is 
paralleled by significant βAR downregulation in the ischemic skeletal muscle. Thus, we tested the in vivo 
properties of Ad-mediated intra-arterial gene transfer of the GRK2 inhibitor βARKct on HI. Importantly, 
our data show that βARKct expression in the ischemic tissue induces a significant increase in blood flow 
recovery and perfusion of the ischemic hindlimb compared to control groups (Saline- and GFP-treated) at 
15 days post-FAR. Of note, this result is associated with a significant increase in capillary density 
suggesting improved post-ischemic angiogenesis. As reported by others (Iaccarino et al., 2005), ischemia 
is associated with significant βAR downregulation and dysfunction in the affected muscle. Consistently, 
in our control groups undergoing HI, βAR density is reduced in the ischemic muscle. However, 15 days 
of βARKct expression significantly improved βAR density in the ischemic hindlimb, almost to levels 
observed in sham-operated rats, thus suggesting a possible explanation for the beneficial effects of this 
therapeutic strategy on in vivo revascularization.  
Since a pivotal role of β2ARs exists for EC function (Iaccarino et al., 2005; Ciccarelli et al., 2011; 
Howell et al., 1988), particularly in respect to the regulation of postnatal ischemic angiogenesis, our 
mechanistic focus targeting GRK2 activity was to investigate the impact of βARKct on EC function in 
vitro. In BAECs, we have observed that GRK2 overexpression, obtained via Ad-mediated gene transfer, 
significantly impairs both cell migration and proliferation in response to selective β2AR stimulation. This 
shows that indeed GRK2 has influence at the level of the β2AR and can be a mediator of dysregulation of 
the system. At the molecular level, these deleterious effects exerted by GRK2 on EC function are 
paralleled by β2AR dysfunctional signaling, as suggested by levels of receptor phosphorylation and 
reduced Akt and eNOS activation following acute fenoterol stimulation (5-15 minutes, respectively). 
Interestingly, following 6 hours of fenoterol stimulation, these negative effects are also observed in GFP 
infected cells, but it is important to underline that at this time-point fenoterol induces a strong up-
regulation of endogenous GRK2 levels (Figure 6). However, after 15 minutes of fenoterol stimulation, a 
time-point where GRK2 is not up-regulated, Ad-GFP treated ECs show reduced levels of p-β2AR and, 
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increased level of Akt and eNOS activation when compared to Ad-GRK2 treated cells, thus indicating 
higher responsiveness to β2AR activation (Figure 5). Of further importance, βARKct expression improves 
EC migration and proliferation and preserves β2AR signaling and function, after fenoterol stimulation 
(Figure 7). These data suggest that βARKct is able to enhance β2AR signaling and to improve EC 
function following fenoterol administration.  
Study limitations. GRK2 has been shown to directly interact with and inhibit both Akt and eNOS (Brinks 
at al., 2010; Huang at al., 2013) therefore, it is quite likely that, some of the observed effects of βARKct 
are due to direct inhibition of GRK2 acting on Akt/eNOS and independently of the β2AR. However, our 
results strongly suggest that acute β2AR stimulation by fenoterol can directly activate Akt and eNOS in 
ECs in vitro and that, while βARKct expression does not affect the acute action of fenoterol, it 
ameliorates later effects of fenoterol on β2AR phosphorylation, enhancing NO release in these cells. 
Moreover, our data obtained in eNOS KO ECs support the hypothesis that the preservation of 
β2AR/eNOS axis is relevant for the positive effects of βARKct in ECs. It is important to underline that we 
cannot exclude any potential involvement of other cell types (i.e. skeletal muscle cells or smooth muscle 
cells) other than ECs and endothelial progenitor cells (EPCs) for which recently has been proposed a 
relevant role in post-ischemic angiogenesis in vivo (Galasso et al., 2013). In this regard, it has been 
recently demonstrated that in C2C12 myoblasts, GRK2 overexpression lead to a significant impairment in 
cell differentiation, thus suggesting for this kinase a relevant role in skeletal muscle myogenesis (Garcia-
Guerra et al 2014). Thus, we cannot exclude additional effects of βARKct in skeletal muscle cells in our 
in vivo model. As an addition limitation, as reported by other previously (Iaccarino et al., 2005) and as 
shown in our immunohistochemistry (Supplemental Figure 1), the gene delivery technique we used 
results in a predominant localization of the transgenes to the existing vascular structures within the 
ischemic tissue. Finally, in our in vivo study we measured total βAR density in the ischemic muscle of 
rats rather than β2AR density. However, the β2AR is known to be the main isoform expressed in EC and 
in the skeletal muscles (Osswald and Guimarães,1983; Guimarães and Moura, 2001; Lynch and Ryall, 
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2008), thus we can assume that part of the effects of HI and βARKct gene therapy on total βAR density 
might be ascribed to changes in β2AR density. Moreover, our in vitro data in ECs have specifically 
investigated the effects of βARKct on β2AR signaling and function, clearly demonstrating a protective 
effect of βARKct on β2AR downregulation. 
In conclusion, in the present study we provide novel evidence that βARKct expression and 
subsequent GRK2 inhibition positively regulates β2AR signaling and function in ECs with relevant 
implications on post-ischemic angiogenesis. For this reason we propose βARKct gene therapy as a new 
therapeutic approach to re-establish blood flow to the limbs affected by critical ischemia. 
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Figure Legends 
Figure 1 
βAR downregulation is associated with increased GRK2 protein levels in the ischemic muscle. 
A) Bar graph showing blood perfusion in the ischemic hindlimb in rats at 15 days post-femoral artery 
resection (HI; n=6) and in sham-operated rats (Sham; n=6), as assessed by dyed beads dilution method. 
Data are expressed as percentage of ischemic to non-ischemic hindlimb; B) Bar graphs showing total 
βAR density on skeletal muscle plasma membrane preparations from rats 15 days post-femoral artery 
resection (HI; n=6) and sham-operated rats (Sham; n=6); C) Representative immunoblots (upper panel) 
and densitometric analysis (lower panel) of multiple (n=3, including 2 samples per group each) 
independent experiments showing GRK2/GAPDH protein levels in skeletal muscle lysates from the 
ischemic hindlimb of rats undergoing femoral artery resection (HI, n=6) and from sham-operated rats 
(Sham, n=6). GAPDH was used as loading control; Data are expressed as mean ± SEM. *p<0.05 vs Sham 
 
Figure 2 
In Vivo gene delivery study design  
A) Overall study design. Rats underwent femoral resection and were randomized to receive intravascular 
injection of Ad-βARKct or Ad-GFP or a saline (vehicle). Hindlimb perfusion was evaluated by US-
Doppler before, immediately after, 3, 7 10 and 15 days post-surgery. B) Rrepresentative 
immunohistochemistry images showing βARKct/endogenous GRK2 expression in skeletal muscle of rats 
treated with Ad-βARKct or saline. βARKct was detected using an anti-GRK2 antibody; Scale bar: 100 
µm C-D) Representative immunoblot (C) and densitometric analysis (D) of multiple independent 
experiment (n=4) to evaluate GRK2 and βARKct expression in skeletal muscle lysates of rats treated with 
Ad-βARKct or saline. GRK2 expression has been normalized with GAPDH, while βARKct expression 
has been expressed as fold of endogenous GRK2 level.  
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Figure 3 
βARKct gene delivery in skeletal muscle improves post-ischemic angiogenesis and restores β2AR 
density. 
A) Blood flow measured by US doppler in the tibial posterior artery of rats (n=6-8 rats for each group) 
over the course of 15 days post-surgery. Data are expressed as percent of ischemic to non-ischemic limb. 
B) Blood perfusion (n=6-8 rats for each group) in the ischemic HL of all 4 study groups as evaluated by 
dyed beads dilution assay performed at the end of the study period (15 day after gene transfer). Perfusion 
data are expressed as ischemic-to-non ischemic ratio percent of dyed beads content per milligram of hind-
limb muscle tissue. C) Representative images of Lectin Bandeiraea simplicifolia I (BS-I) staining of 
capillaries in the ischemic hindlimb (Left panels; Scale bar: 100 µm) and bar graph (right panel) showing 
Capillary-to-myocyte ratio in ischemic muscles (n=8 each group) of all 4 groups and in sham-operated 
rats, as control. Arrows indicate capillaries; D) βAR plasma membrane density in skeletal muscle 
homogenates, purified from hindlimb (n=6 rats for each group) from Sham and ischemic groups (Saline, 
GFP and βARKct) at 15 days after surgery and gene delivery.  
*p<0.05 vs Sham; # p< 0.05 vs Saline and GFP. 
 
Figure 4 
Fenoterol selectively stimulates endothelial β2AR pro-angiogenic signaling in BAECs. 
A-B) Representative immunoblots (upper panels) and densitometric quantitative analysis (lower panel) of 
multiple (n=3) independent experiments to evaluate in bovine aortic endothelial cells (BAECs) 
unstimulated (Ns) or stimulated with fenoterol (Fen, 1 µM) for 15 minutes: (A) Akt phosphorylation 
levels on serine 473 (ser473p-Akt) and (B) eNOS phosphorylation levels on serine 1177 (ser1177p-eNOS) and 
total protein levels. Total Akt and total e-NOS served as loading controls, respectively. Prior to Fen 
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stimulation a group of cells was pre-treated with selective β2AR antagonist ICI-118,551 (ICI, 10 µM). 
*p<0.05 vs Ns.  
 
Figure 5 
Effects of GRK2 levels on β2AR phosphorylation and Akt and eNOS activation following Fen 
stimulation in BAECs.  
A-B-C-D) Representative immunoblots (upper) and densitometric analysis (bottom) of multiple 
independent experiments (n=3) to evaluate: (A) β2AR phosphorylation levels on threonine 384 (thr384p-
β2AR), (B) ser473p-Akt and (C) ser1177p-eNOS and total protein levels of (D) GRK2 in total lysates of 
BAECs, infected with adenoviruses (Ad) encoding for GFP, GRK2 or βARKct. Cells were Ns of 
stimulated with Fen (1 μM) respectively for 5 minutes (A) or 15 minutes (B-C-D). Total β2AR, total Akt, 
total eNOS and GAPDH served as loading controls. Data are expressed as mean ± SEM. *p<0.05 vs GFP 
Ns;  # p< 0.05 vs GFP Fen. 
Figure 6 
Long-term effects of Fen stimulation on β2AR function in BAECs. 
A-B-C-D) Densitometric analysis of multiple independent experiments to evaluate (A) GRK2 protein 
levels and thr384p-β2AR (B) ser473p-Akt (C) ser1177p-eNOS (D) in total lysates of BAECs, infected with 
adenoviruses (Ad) encoding for GFP, GRK2 or βARKct. Cells were Ns of stimulated with Fen (1 μM) 
respectively for 6 hours (A-B-C-D). GAPDH, total β2AR, total Akt and total eNOS served as loading 
controls, respectively; *p<0.05 vs GFP Ns; #p<0.05 vs GRK2.  
 
Figure 7 
βARKct prevents fenoterol-induced β2AR-internalization in BAECs. 
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A-B) Representative immunoblots (A) and densitometric quantitative analysis (B) of multiple (n=3) 
independent experiments to evaluate β2AR levels in crude plasma membrane preparations and in cytosolic 
fraction obtained from BAECs infected with Ad-GFP and Ad-βARKct. Cells were not stimulated (Ns) or 
stimulated with Fen (1 μM) for 6 hours. *p<0.05 vs GFP Ns; #p<0.05 vs GFP Fen; C) Representative 
immunofluorescence images (Scale bar: 10 µm) of β2AR in BAECs infected with Ad-GFP and Ad-
βARKct. Cells were Ns or treated for 6 hours with Fen (1 μM). Arrows indicate receptors that are 
internalized.  
 
Figure 8 
The presence of βARKct enhances BAEC function.  
A) Bar graph showing Nitric Oxide (NO) release in the media obtained from BAECs infected with Ad-
GFP and –βARKct, Ns or stimulated with Fen (1 μM) for 6 hours. *p<0.05 vs GFP Ns; # p< 0.05 vs GFP 
Fen. B) Representative images (upper; Scale bar: 25 µm) and bar graphs (lower) showing percentage of 
cell migration in response to 6 hours of Fen (1 µM) stimulation, evaluated by wound healing scratch 
assay. Confluent monolayers of BAECs infected with Ad-GFP and –βARKct were wounded at time 0 (T 
= 0). The average rate of wound closure during the first 6 hours of wound healing was calculated from 
n=3 independent experiments; *p<0.05 vs GFP Ns; # p< 0.05 vs GFP Fen. C) BrdU proliferation assay in 
BAECs, infected with Ad-GFP and –βARKct, at different time points (0, 6 and 24 hours) of stimulation 
with Fen (1 µM). Results are expressed as percentage of proliferation over Ns cells; *p<0.05 vs GFP Ns; 
# p< 0.05 vs GFP Fen. 
 
Figure 9 
The lack of eNOS prevents the effects of βARKct in ECs 
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Murine aortic endothelial cells (ECs), isolated from Wild-type (WT) and eNOS KO mice, infected with 
Ad-GFP or -βARKct, Ns or stimulated with Fen (1 μM). A) Bar graphs (lower) showing percentage of 
cell migration, evaluated by wound healing scratch assay. Confluent monolayers of ECs were wounded at 
time 0 (T = 0). The average rate of wound closure during the first 6 hours of wound healing was 
calculated from n=3 independent experiments; B) BrdU proliferation assay in ECs at different time points 
(0, 6 and 24 hours). Results are expressed as percentage of proliferation over Ns cells; *p<0.05 vs GFP 
Ns; # p< 0.05 vs GFP Fen; ^p<0.05 vs WT GFP; C) Bar graph showing Nitric Oxide (NO) release in the 
media from ECs stimulated with Fen (1 μM) for 6 hours. *p<0.05 vs WT GFP; # p< 0.05 vs WT βARKct. 
 









